Cargando…

Postviral Complications: Bacterial Pneumonia

Secondary bacterial pneumonia after viral respiratory infection remains a significant source of morbidity and mortality. Susceptibility is mediated by a variety of viral and bacterial factors, and complex interactions with the host immune system. Prevention and treatment strategies are limited to in...

Descripción completa

Detalles Bibliográficos
Autores principales: Prasso, Jason E., Deng, Jane C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Health Sciences Division 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324726/
https://www.ncbi.nlm.nih.gov/pubmed/28159155
http://dx.doi.org/10.1016/j.ccm.2016.11.006
_version_ 1782510257979785216
author Prasso, Jason E.
Deng, Jane C.
author_facet Prasso, Jason E.
Deng, Jane C.
author_sort Prasso, Jason E.
collection PubMed
description Secondary bacterial pneumonia after viral respiratory infection remains a significant source of morbidity and mortality. Susceptibility is mediated by a variety of viral and bacterial factors, and complex interactions with the host immune system. Prevention and treatment strategies are limited to influenza vaccination and antibiotics/antivirals respectively. Novel approaches to identifying the individuals with influenza who are at increased risk for secondary bacterial pneumonias are urgently needed. Given the threat of further pandemics and the heightened prevalence of these viruses, more research into the immunologic mechanisms of this disease is warranted with the hope of discovering new potential therapies.
format Online
Article
Text
id pubmed-5324726
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier Health Sciences Division
record_format MEDLINE/PubMed
spelling pubmed-53247262018-03-01 Postviral Complications: Bacterial Pneumonia Prasso, Jason E. Deng, Jane C. Clin Chest Med Article Secondary bacterial pneumonia after viral respiratory infection remains a significant source of morbidity and mortality. Susceptibility is mediated by a variety of viral and bacterial factors, and complex interactions with the host immune system. Prevention and treatment strategies are limited to influenza vaccination and antibiotics/antivirals respectively. Novel approaches to identifying the individuals with influenza who are at increased risk for secondary bacterial pneumonias are urgently needed. Given the threat of further pandemics and the heightened prevalence of these viruses, more research into the immunologic mechanisms of this disease is warranted with the hope of discovering new potential therapies. Elsevier Health Sciences Division 2017-03 2016-12-13 /pmc/articles/PMC5324726/ /pubmed/28159155 http://dx.doi.org/10.1016/j.ccm.2016.11.006 Text en Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Prasso, Jason E.
Deng, Jane C.
Postviral Complications: Bacterial Pneumonia
title Postviral Complications: Bacterial Pneumonia
title_full Postviral Complications: Bacterial Pneumonia
title_fullStr Postviral Complications: Bacterial Pneumonia
title_full_unstemmed Postviral Complications: Bacterial Pneumonia
title_short Postviral Complications: Bacterial Pneumonia
title_sort postviral complications: bacterial pneumonia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324726/
https://www.ncbi.nlm.nih.gov/pubmed/28159155
http://dx.doi.org/10.1016/j.ccm.2016.11.006
work_keys_str_mv AT prassojasone postviralcomplicationsbacterialpneumonia
AT dengjanec postviralcomplicationsbacterialpneumonia